Hangzhou Coben Pharmaceutical

Hangzhou Coben Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, and commercialization of innovative small molecule drugs, with a primary focus on digestive system disorders. The company's flagship product is Keveprazan (CP601), a novel potassium-competitive acid blocker (P-CAB) developed for the treatment of acid-related diseases such as gastric ulcers and reflux esophagitis. Coben Pharmaceutical operates integrated facilities for R&D and manufacturing, aiming to provide high-quality, affordable therapeutic solutions for the domestic and international markets. Their pipeline also includes several generic and improved formulations targeting various gastrointestinal and metabolic conditions.